Hemophilia a treatment comparison study canceled before starting
NCT ID NCT04690322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to compare two standard treatments for severe hemophilia A in children: extended half-life factor VIII and non-factor VIII therapies. Researchers planned to measure how well each treatment prevented bleeding and protected joint health using ultrasound. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACTOR VIII are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Can an ultra-long-acting factor VIII simplify surgery for hemophilia a patients?
- Do newer hemophilia drugs protect joints better? study aims to find out
- Newborn screening study aims to catch rare diseases at birth
- Could home blood tests transform hemophilia care? study seeks patient views